This site is intended for healthcare professionals
A close up image of a microscope
  • Home
  • /
  • Clinical trials
  • /
  • Lynparza
  • /
  • Assessment of the Efficacy and Safety of Olaparib ...
Clinical trial

Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations. (OlympiAD)

Read time: 2 mins
Last updated:27th Mar 2014
Identifier: NCT02000622

This open label, randomised, controlled, multi-centre phase III study will assess the efficacy and safety of single agent olaparib vs standard of care based on physician's choice of capecitabine, vinorelbine or eribulin in metastatic breast cancer patients with gBRCA 1/2 mutations.


Study Type: Interventional  (Clinical Trial)
Actual Enrollment: 302 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase III, Open Label, Randomised, Controlled, Multi-centre Study to Assess the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.
Actual Study Start Date: March 27, 2014
Actual Primary Completion Date: December 9, 2016
Estimated Study Completion Date: December 31, 2019

Arms:
- Experimental:
Olaparib
- Active Comparator: Physician's choice chemotherapy

Category Value
Date last updated at source 2019-06-07
Study type(s) Interventional
Expected enrolment 302
Study start date 2014-03-27
Estimated primary completion date 2016-12-09

View full details